fenchone hydrazone | 73509-03-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: fenchone hydrazone
• 英文别名: (1,3,3-Trimethylbicyclo[2.2.1]heptan-2-ylidene)hydrazine；(1,3,3-trimethyl-2-bicyclo[2.2.1]heptanylidene)hydrazine
• CAS: 73509-03-2
• 化学式: C₁₀H₁₈N₂
• 分子量: 166.266
• InChiKey: PAIGSTUXPRTCJO-UHFFFAOYSA-N

物化性质

• 沸点：
  244.8±23.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  fenchone hydrazone 在 三正丁胺 、 乙基溴化镁 、 二氯化二硒 作用下， 生成 Selenofenchone
  参考文献：
  名称：

  一种新的，便捷的硒酮合成方法

  摘要：

  tri的二镁盐在三正丁胺的存在下与Se 2 Cl 2反应，以中等至良好的收率得到硒酮。

  DOI：

  10.1039/c39830001429
• 作为产物：
  描述：

  (+)-葑酮 在 一水合肼 作用下， 生成 fenchone hydrazone
  参考文献：
  名称：

  Wolff, Justus Liebigs Annalen der Chemie, 1912, vol. 394, p. 85

  摘要：

  DOI：

文献信息

• Reactions of Ketone Hydrazones and β-Keto Enamines with Disulfur Dichloride. New Synthesis of Thioketones and 5<i>H</i>-1,2,3-Dithiazoles
  作者：Renji Okazaki、Kaoru Inoue、Naoki Inamoto

  DOI：10.1246/bcsj.54.3541

  日期：1981.11

  to afford thioketones in good yields. The reaction mechanism involving N-thiosulfinylamine (R2C=N–N=S=S) and S-thioxothioketone (R2C=S=S) is proposed. The formation of t-butyl and di-1-adamantyl thioketones even at low temperatures has been interpreted as steric congestion alone being not enough to stabilize the corresponding S-thioxothioketones. The reaction of β-ketoenamines with disulfur dichloride

  酮腙与二氯化二硫在三乙胺存在下反应，以良好的收率得到硫酮。提出了涉及N-硫代亚磺胺（R2C=N-N=S=S）和S-硫代硫酮（R2C=S=S）的反应机理。即使在低温下，叔丁基和二-1-金刚烷基硫酮的形成也被解释为单独的空间拥挤不足以稳定相应的 S-硫代硫酮。β-酮烯胺与二氯化二硫反应通过中间体 N-硫代亚磺胺的分子内环化得到 5H-1,2,3-二噻唑。
• Reaction of Seleno- or Thiofenchone with Propiolic Acid: Wagner-Meerwein Rearrangement
  作者：Kentaro Okuma、Hiroyuki Matsui、Yuichi Mori

  DOI：10.1002/hc.21181

  日期：2014.11

  A reaction of selenofenchone with propiolic acid in refluxing chloroform produced 1,3-oxaselenin-6-one, which further reacted with acid to afford the ring-opened product. A reaction of 1,3-oxathiin-6-one prepared from thiofenchone with trifluoroacetic acid gave a Wagner–Meerwein rearranged product. In the presence of AlCl3, thiofenchone reacted with methyl propiolate to afford the corresponding rearranged

  selenofenchone 与丙炔酸在回流氯仿中反应生成 1,3-oxaselenin-6-one，1,3-oxaselenin-6-one 进一步与酸反应得到开环产物。由噻吩酮制备的 1,3-oxathiin-6-one 与三氟乙酸反应得到 Wagner-Meerwein 重排产物。在 AlCl3 存在下，噻吩酮与丙炔酸甲酯反应得到相应的重排酯。
• Synthesis and Reactions of Selenoketones
  作者：Akihiko Ishii、Renji Okazaki、Naoki Inamoto

  DOI：10.1246/bcsj.61.861

  日期：1988.3

  reported. The reaction of dimagnesium salts of ketone hydrazones with diselenium dichloride affords an intermediate tentatively assigned as tetraselenides, which are converted into selenoketones by heating in the presence of tributylamine. A comparative study on the reactions of 1,1,3,3-tetramethyl-2-indanselone and the corresponding thioketone with Grignard and organolithium reagents have been carried

  已经报道了一种新的、方便的合成硒酮的方法。酮腙的二镁盐与二氯化二硒反应得到暂定为四硒化物的中间体，通过在三丁胺存在下加热将其转化为硒酮。对1,1,3,3-四甲基-2-茚满酮和相应的硫酮与格氏试剂和有机锂试剂的反应进行了对比研究。对反应产物的分析表明，在与 selone 的反应中，有机金属试剂的异嗜性攻击比与硫酮的反应要显着得多。
• Nitric oxide donors, compositions and methods of use related applications
  申请人：——

  公开号：US20030203915A1

  公开（公告）日：2003-10-30

  The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

  该发明描述了新型一氧化氮供体和至少包含一种一氧化氮供体的新型组合物。该发明还提供了包含至少一种一氧化氮供体和（或）至少一种治疗剂的新型组合物。该发明中的化合物和组合物也可以与基质结合。该发明还提供了治疗心血管疾病、抑制血液暴露于医疗设备引起的血小板聚集和粘附、治疗由异常细胞增殖引起的病理状况、移植排斥、自身免疫、炎症、增生、高增生、血管疾病、减少瘢痕组织或抑制创伤收缩、特别是通过给予一氧化氮供体的预防性和/或治疗性治疗至少一种治疗剂的方法，以及治疗炎症、疼痛、发热、胃肠障碍、呼吸系统障碍和性功能障碍的方法。一氧化氮供体可以捐赠、转移或释放一氧化氮，并/或提高内皮源性舒张因子的内源性水平，并/或刺激内源性一氧化氮的合成，并且是一氧化氮合酶的底物，能够在生理条件下释放一氧化氮或间接地向靶点输送或转移一氧化氮。治疗剂可以选择性地用至少一种NO和/或NO2基（即硝酰化和/或硝化）替换。该发明还提供了至少包含一种一氧化氮供体和/或至少一种治疗剂的新型组合物和工具包。
• Kishner, Zhurnal Russkago Fiziko-Khimicheskago Obshchestva, 1911, vol. 43, p. 594
  作者：Kishner

  DOI：——

  日期：——